Fisher & Paykel Healthcare (ASX:FPH) EBITDA per Share: A$1.17 (TTM As of Mar. 2026)


ASX:FPH Fisher & Paykel Healthcare Corp Ltd ASX:FPH
88 GF Score
Price A$31.81
GF Value A$36.35
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Fisher & Paykel Healthcare EBITDA per Share?

Fisher & Paykel Healthcare ASX:FPH -0.75% 88 EBITDA per Share is A$1.17 as of Mar. 2026. GuruFocus rates ASX:FPH with a GF Score™ of 88/100 and a GF Value™ of A$36.35 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 696 Medical Devices & Instruments companies, Fisher & Paykel Healthcare ranks better than 68.39% on this metric.

Fisher & Paykel Healthcare's EBITDA per Share for the six months ended in Mar. 2026 was A$0.62. Its EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2026 was A$1.17.

During the past 12 months, the average EBITDA per Share Growth Rate of Fisher & Paykel Healthcare was 22.30% per year. During the past 3 years, the average EBITDA per Share Growth Rate was 22.10% per year. During the past 5 years, the average EBITDA per Share Growth Rate was -0.40% per year. During the past 10 years, the average EBITDA per Share Growth Rate was 9.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Fisher & Paykel Healthcare's EBITDA per Share or its related term are showing as below:

ASX:FPH' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -23.3   Med: 10.7   Max: 51.7
Current: 22.1

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Fisher & Paykel Healthcare was 51.70% per year. The lowest was -23.30% per year. And the median was 10.70% per year.

ASX:FPH's 3-Year EBITDA Growth Rate is ranked better than
68.39% of 696 companies
in the Medical Devices & Instruments industry
Industry Median: 7.8 vs ASX:FPH: 22.10

Fisher & Paykel Healthcare's EBITDA for the six months ended in Mar. 2026 was A$364 Mil.

During the past 12 months, the average EBITDA Growth Rate of Fisher & Paykel Healthcare was 22.30% per year. During the past 3 years, the average EBITDA Growth Rate was 22.70% per year. During the past 5 years, the average EBITDA Growth Rate was 0.10% per year. During the past 10 years, the average EBITDA Growth Rate was 10.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Fisher & Paykel Healthcare was 53.50% per year. The lowest was -23.10% per year. And the median was 11.10% per year.


Fisher & Paykel Healthcare  (ASX:FPH) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Fisher & Paykel Healthcare EBITDA per Share Related Terms


Fisher & Paykel Healthcare EBITDA per Share Historical Data

* Premium members only.

The historical data trend for Fisher & Paykel Healthcare's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fisher & Paykel Healthcare EBITDA per Share Chart

Fisher & Paykel Healthcare Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBITDA per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.97 0.69 0.58 1.01 1.13

Fisher & Paykel Healthcare Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.26 0.44 0.58 0.55 0.62
ASX:FPH
88GF Score
Fisher & Paykel Healthcare Corp Ltd ASX:FPH
EBITDA per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fisher & Paykel Healthcare EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Fisher & Paykel Healthcare's EBITDA per Share for the fiscal year that ended in Mar. 2026 is calculated as

EBITDA per Share(A: Mar. 2026 )
=EBITDA/Shares Outstanding (Diluted Average)
=667/590.794
=1.13

Fisher & Paykel Healthcare's EBITDA per Share for the quarter that ended in Mar. 2026 is calculated as

EBITDA per Share(Q: Mar. 2026 )
=EBITDA/Shares Outstanding (Diluted Average)
=363.5/589.922
=0.62

EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$1.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA per Share →
What does a EBITDA per Share of A$1.17 mean?
Fisher & Paykel Healthcare (ASX:FPH) has a EBITDA per Share of A$1.17 as of Mar. 2026. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Fisher & Paykel Healthcare and its competitors. According to the industry distribution chart, Fisher & Paykel Healthcare ranks #220 out of 696 companies in the Medical Devices & Instruments industry, placing it in the top 31.6%.
Is Fisher & Paykel Healthcare's EBITDA per Share too high?
Fisher & Paykel Healthcare's current EBITDA per Share is A$1.17. Based on the distribution chart, Fisher & Paykel Healthcare ranks #220 out of 696 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Fisher & Paykel Healthcare has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's EBITDA per Share compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Fisher & Paykel Healthcare ranks #220 out of 696 companies for EBITDA per Share. This puts Fisher & Paykel Healthcare in the upper half of its industry. The industry median EBITDA per Share is 7.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA per Share for a Medical Devices & Instruments company?
The median EBITDA per Share among Medical Devices & Instruments companies is 7.80, based on 696 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA per Share significantly above this median, while those in the bottom quartile fall well below. However, EBITDA per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA per Share mean?
A high EBITDA per Share can signal that a stock is expensive relative to its fundamentals. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Fisher & Paykel Healthcare and its competitors. For the Medical Devices & Instruments industry, the median EBITDA per Share is 7.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fisher & Paykel Healthcare's current EBITDA per Share is A$1.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare (ASX:FPH) is currently considered Modestly Undervalued. The stock's GF Value™ is A$36.35, compared to a current price of A$31.81 — trading 12.5% below its estimated fair value. The current EBITDA per Share is A$1.17. Fisher & Paykel Healthcare's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA per Share calculated?
EBITDA per Share is calculated from a company's financial statements. For Fisher & Paykel Healthcare (ASX:FPH), the current EBITDA per Share is A$1.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fisher & Paykel Healthcare (ASX:FPH) Overvalued in 2026?

Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued. The current stock price of A$31.81 is trading 12.5% below its estimated GF Value™ of A$36.35. GuruFocus considers Fisher & Paykel Healthcare to be Modestly Undervalued.

Key valuation signals for ASX:FPH:

  • EBITDA per Share: A$1.17
  • GF Value™: A$36.35 vs. price of A$31.81 (12.5% below fair value)
  • GF Score™: 88/100 with 2 warning signs

No single metric tells the full story. See the ASX:FPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fisher & Paykel Healthcare Business Description

Other Exchanges FSPKF:USAFPH:New Zealand
Address 15 Maurice Paykel Place, East Tamaki, Auckland, NTL, NZL, 2013
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
88GF Score

Get the complete analysis for ASX:FPH

EBITDA per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$31.81
Price
A$36.35
GF Value